DK3347353T3 - Pyrazolyl-substituerede heteroaryler og deres anvendelse som lægemidler - Google Patents
Pyrazolyl-substituerede heteroaryler og deres anvendelse som lægemidler Download PDFInfo
- Publication number
- DK3347353T3 DK3347353T3 DK16759802.8T DK16759802T DK3347353T3 DK 3347353 T3 DK3347353 T3 DK 3347353T3 DK 16759802 T DK16759802 T DK 16759802T DK 3347353 T3 DK3347353 T3 DK 3347353T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrazolyl
- medicines
- substituted heteroaryls
- heteroaryls
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217269P | 2015-09-11 | 2015-09-11 | |
| PCT/EP2016/070729 WO2017042100A1 (en) | 2015-09-11 | 2016-09-02 | Pyrazolyl-substituted heteroaryls and their use as medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3347353T3 true DK3347353T3 (da) | 2019-10-21 |
Family
ID=56852283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16759802.8T DK3347353T3 (da) | 2015-09-11 | 2016-09-02 | Pyrazolyl-substituerede heteroaryler og deres anvendelse som lægemidler |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9845314B2 (da) |
| EP (1) | EP3347353B1 (da) |
| JP (1) | JP6868011B2 (da) |
| KR (1) | KR20180051624A (da) |
| CN (1) | CN108026080B (da) |
| AR (1) | AR105991A1 (da) |
| AU (1) | AU2016320297B2 (da) |
| CA (1) | CA2998250A1 (da) |
| CL (1) | CL2018000400A1 (da) |
| DK (1) | DK3347353T3 (da) |
| EA (1) | EA033978B1 (da) |
| ES (1) | ES2745284T3 (da) |
| HU (1) | HUE046920T2 (da) |
| IL (1) | IL257392B (da) |
| MX (1) | MX2018003008A (da) |
| PH (1) | PH12018500533A1 (da) |
| PL (1) | PL3347353T3 (da) |
| TW (1) | TW201720799A (da) |
| WO (1) | WO2017042100A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体の使用 |
| JP2017504653A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアミノピリミジンベンゼンスルホン誘導体およびその使用 |
| LT3119772T (lt) * | 2014-03-19 | 2019-08-26 | Boehringer Ingelheim International Gmbh | Heteroarilo sik inhibitoriai |
| KR20180051576A (ko) | 2015-09-11 | 2018-05-16 | 다나-파버 캔서 인스티튜트 인크. | 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도 |
| DK3347353T3 (da) | 2015-09-11 | 2019-10-21 | Boehringer Ingelheim Int | Pyrazolyl-substituerede heteroaryler og deres anvendelse som lægemidler |
| RU2750164C2 (ru) | 2015-09-11 | 2021-06-22 | Дана-Фарбер Кэнсер Инститьют, Инк. | Цианотиенотриазолодиазепины и пути их применения |
| WO2017091673A2 (en) | 2015-11-25 | 2017-06-01 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibtors and uses thereof |
| TW201927769A (zh) * | 2017-12-18 | 2019-07-16 | 德商歌林達有限公司 | 經取代之吡咯啶醯胺ｉｉ |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| US20220133734A1 (en) | 2020-11-02 | 2022-05-05 | Boehringer Ingelheim International Gmbh | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
| CN115197115A (zh) * | 2022-08-25 | 2022-10-18 | 成都金博汇康医药科技有限公司 | 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| EP1799673A1 (en) * | 2004-10-15 | 2007-06-27 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| EP1871766A4 (en) * | 2005-03-30 | 2010-07-21 | Dae Woong Pharma | TRIAZONE DERIVATIVES WITH ANTIPILY EFFECT |
| CA2732087A1 (en) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and their use as medicaments |
| JP5754568B2 (ja) | 2008-08-05 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−ジメチルアミノ−フェニルで置換されているナフチリジン、及び医薬としてのその使用 |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| SG10201707798SA (en) * | 2008-12-08 | 2017-10-30 | Gilead Connecticut Inc | Imidazopyrazine syk inhibitors |
| EA201201052A1 (ru) | 2010-01-29 | 2013-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| MX342310B (es) | 2011-03-28 | 2016-09-26 | Hoffmann La Roche | Compuestos de tiazolopirimidina. |
| BR112014001898A2 (pt) | 2011-07-26 | 2017-02-21 | Boehringer Ingelheim Int | quinolinas substituídas e seu uso como medicamentos |
| EP2762476A4 (en) * | 2011-09-30 | 2015-03-25 | Taiho Pharmaceutical Co Ltd | 1,2,4-triazine-6-carboxamide derivative |
| WO2013182546A1 (en) | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase |
| WO2014100113A2 (en) | 2012-12-18 | 2014-06-26 | Hulow, Llc | Syk kinase inhibitors as treatment for malaria |
| US9376441B2 (en) * | 2013-07-31 | 2016-06-28 | Gilead Sciences, Inc. | Substituted pyrrolidines as SYK inhibitors |
| WO2015104662A1 (en) * | 2014-01-10 | 2015-07-16 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| LT3119772T (lt) | 2014-03-19 | 2019-08-26 | Boehringer Ingelheim International Gmbh | Heteroarilo sik inhibitoriai |
| TW201617074A (zh) * | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Ｓｙｋ（脾酪胺酸激酶）抑制劑 |
| DK3347353T3 (da) | 2015-09-11 | 2019-10-21 | Boehringer Ingelheim Int | Pyrazolyl-substituerede heteroaryler og deres anvendelse som lægemidler |
-
2016
- 2016-09-02 DK DK16759802.8T patent/DK3347353T3/da active
- 2016-09-02 EA EA201890695A patent/EA033978B1/ru not_active IP Right Cessation
- 2016-09-02 ES ES16759802T patent/ES2745284T3/es active Active
- 2016-09-02 HU HUE16759802A patent/HUE046920T2/hu unknown
- 2016-09-02 CN CN201680052766.1A patent/CN108026080B/zh active Active
- 2016-09-02 WO PCT/EP2016/070729 patent/WO2017042100A1/en active Application Filing
- 2016-09-02 MX MX2018003008A patent/MX2018003008A/es active IP Right Grant
- 2016-09-02 KR KR1020187010299A patent/KR20180051624A/ko unknown
- 2016-09-02 US US15/255,283 patent/US9845314B2/en active Active
- 2016-09-02 CA CA2998250A patent/CA2998250A1/en not_active Abandoned
- 2016-09-02 JP JP2018512594A patent/JP6868011B2/ja active Active
- 2016-09-02 AU AU2016320297A patent/AU2016320297B2/en not_active Ceased
- 2016-09-02 EP EP16759802.8A patent/EP3347353B1/en active Active
- 2016-09-02 PL PL16759802T patent/PL3347353T3/pl unknown
- 2016-09-09 AR ARP160102777A patent/AR105991A1/es unknown
- 2016-09-10 TW TW105129440A patent/TW201720799A/zh unknown
-
2017
- 2017-11-10 US US15/809,163 patent/US10155751B2/en active Active
-
2018
- 2018-02-07 IL IL257392A patent/IL257392B/en active IP Right Grant
- 2018-02-14 CL CL2018000400A patent/CL2018000400A1/es unknown
- 2018-03-12 PH PH12018500533A patent/PH12018500533A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE046920T2 (hu) | 2020-03-30 |
| JP2018529679A (ja) | 2018-10-11 |
| AR105991A1 (es) | 2017-11-29 |
| KR20180051624A (ko) | 2018-05-16 |
| US20170073333A1 (en) | 2017-03-16 |
| AU2016320297A1 (en) | 2018-02-08 |
| EP3347353B1 (en) | 2019-07-17 |
| CN108026080B (zh) | 2021-06-11 |
| US9845314B2 (en) | 2017-12-19 |
| PH12018500533A1 (en) | 2018-09-10 |
| ES2745284T3 (es) | 2020-02-28 |
| EA201890695A1 (ru) | 2018-09-28 |
| IL257392A (en) | 2018-04-30 |
| JP6868011B2 (ja) | 2021-05-12 |
| PL3347353T3 (pl) | 2020-01-31 |
| IL257392B (en) | 2020-05-31 |
| CN108026080A (zh) | 2018-05-11 |
| US20180148433A1 (en) | 2018-05-31 |
| CA2998250A1 (en) | 2017-03-16 |
| EA033978B1 (ru) | 2019-12-16 |
| CL2018000400A1 (es) | 2018-07-13 |
| US10155751B2 (en) | 2018-12-18 |
| EP3347353A1 (en) | 2018-07-18 |
| MX2018003008A (es) | 2018-04-11 |
| AU2016320297B2 (en) | 2020-08-27 |
| TW201720799A (zh) | 2017-06-16 |
| WO2017042100A1 (en) | 2017-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3277681T3 (da) | Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer | |
| NO2023013I1 (no) | Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent | |
| DK3347353T3 (da) | Pyrazolyl-substituerede heteroaryler og deres anvendelse som lægemidler | |
| DK3407888T3 (da) | Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser | |
| DK3307707T3 (da) | Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider | |
| DK3354282T3 (da) | Glycan-terapeutiske midler og relaterede fremgangsmåder deraf | |
| DK3328880T3 (da) | Terapeutiske midler | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3149001T3 (da) | Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere | |
| DK3302471T3 (da) | Tetrasubstituerede alkenforbindelser og deres anvendelse | |
| DK3099172T3 (da) | Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3183260T3 (da) | Modificerede oligonukleotider og fremgangsmåder til deres syntese | |
| DK3274430T3 (da) | Mikroalgesammensætninger og deres anvendelser | |
| BR112016018062A2 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| DK3137168T3 (da) | Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
| DK3223796T3 (da) | Farmaceutiske sammensætninger, fremstilling og anvendelser deraf | |
| DK3334576T3 (da) | Stavelement | |
| DK3131577T3 (da) | Modificerede værtsceller og anvendelser deraf | |
| DK3326463T3 (da) | Midesammensætning og anvendelse deraf som biologisk bekæmpelsesmiddel | |
| DK3256479T3 (da) | 4-substituerede benzoxaborolforbindelser og anvendelser deraf | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| DK3229843T3 (da) | Farmaceutisk sammensætning, præparat og anvendelser deraf |